What is already known about this topic?

During August–October 2022, CDC recommended a bivalent COVID-19 mRNA vaccine dose for all persons aged ≥5 years who had received a monovalent primary vaccination series.

What is added by this report?

During December 2022–April 2023, CDC made recommendations for a single bivalent vaccine dose for most persons aged ≥6 years, bivalent vaccines for children aged 6 months–5 years, and optional additional bivalent booster doses for moderately or severely immunocompromised persons aged ≥6 months and adults aged ≥65 years.

What are the implications for public health practice?

Transition to a single bivalent COVID-19 vaccine dose for most persons, with additional doses for persons at increased risk for severe disease, facilitates implementation of simpler, more flexible recommendations. All persons aged ≥6 months should receive ≥1 bivalent vaccine dose.

  • Recommendation
  • Americas
  • United States of America
  • COVID-19